SMC accepts oritavancin for acute bacterial skin and skin structure infections in adults
Oritavancin is accepted for restricted use within NHS Scotland.
Specialist info: Dermatology
For specialist doctors — explore our latest news, features and CPD on this topic.
SMC accepts upadacitinib (Rinvoq®) for moderate to severe atopic dermatitis
Upadacitinib is accepted for restricted use within NHS Scotland, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
SMC accepts treatment for moderate-to-severe atopic dermatitis
Tralokinumab is accepted for restricted use within NHS Scotland.
Company-led medicines recall: Dermaved Sensitive Cream (unlicensed medicine)
The MHRA says Dermaved is recalling this product from patients due to presence of clobetasol propionate (0.001% w/w).
Painful ulceration on the genital area
A 27-year-old female patient comes to see you complaining of a painful “lump down below". What are the possible diagnoses?
NICE approves first treatment in pilot of new approach to cost-comparison fast track appraisals
Bimekizumab is recommended for treating severe plaque psoriasis in draft NICE guidance, which was developed using a new way to review appraisals.
Drug Safety Update: oral retinoid medicines (isotretinoin▼, alitretinoin▼, and acitretin▼)
Temporary monitoring advice during coronavirus (COVID-19) pandemic.
Two dermatology treatments accepted for use within NHS Scotland
SMC accepts 5-aminolevulinic acid for actinic keratoses, and baricitinib, for restricted use, for atopic dermatitis.
SMC accepts treatment for mycosis fungoides-type cutaneous T-cell lymphoma
Research showed that chlormethine hydrochloride was non-inferior to a compounded chlormethine ointment.
